Downstream of Ozempic — The 2nd, 3rd, and 4th Order Effects
PriyankaTwo years into the GLP-1 era the easy trade is over. "Long the manufacturer" is priced -- Lilly and Novo have been the most-owned pharma stocks on the planet since 2023. The trade now is every category downstream of a body composition shift happening at scale, and the proof that the downstream is finally legible in public markets arrived on June 2 with Victoria's Secret's Q1 print.
The signal: Victoria's Secret Q1 2026
The numbers, from the press release:
- Net sales up 15% to $1.560 billion, beating guidance
- Operating income of $76 million, adjusted $80 million, both above guide
- Full-year guidance raised to $7.030 to $7.130 billion in net sales and $550 to $580 million in adjusted operating income
This is the first earnings cycle where you can point at a public company and say this number exists because of GLP-1s. Everybody now has the data. We got there early. The trade is what comes next.
The first-order recap (one paragraph)
Roughly 15 million Americans are on a branded GLP-1 (Wegovy, Ozempic, Mounjaro, Zepbound) as of early 2026. Compounded GLP-1s expanded the addressable market three to five times at the bottom of the price band before the FDA tightened the screws. RFK Jr.'s HHS moved 14 previously banned peptides back into legal status in early 2026, and the July 2026 PCAC vote on Category 2 peptide compounding will determine the shape of the supply chain for the next decade. Search volume on peptides is up roughly 6x off a 2023 base. The heaviest GLP-1 user cohort is Gen X women aged 50 to 64, but adoption is broadening fast among millennial women and, more quietly, men.
Everything below is what happens downstream of those numbers.
Second-order: categories already moving
Apparel refresh cycles. Intimates is the lead -- VS, Skims, Knix, ThirdLove, Cuup -- but the wave is moving into denim (Levi's called it out on the call, Madewell, Frame), swim (Andie, Summersalt), and athleisure (Alo, Vuori, Set Active). A two-size body change inside 12 months is a full wardrobe event. Resale platforms (The RealReal, Vestiaire, Poshmark) get supply-side benefit from the same dynamic.
Facial aesthetics -- "Ozempic face" and the procedure market that fixes it. Volume loss in the cheeks and temples is the most visible side effect of rapid weight loss, and the in-office derm category has responded. Galderma (Restylane, Sculptra) and AbbVie/Allergan (Juvederm) are the duopoly on injectables; the consumer telehealth/derm layer routing patients into clinics includes Ever/Body, Skin Spirit, and platforms like Moxie on the supply side enabling more independent injectors.
Body composition layer. Lean mass preservation is the new mandate -- every clinician treating a GLP-1 patient now recommends resistance training and high protein intake. Strength brands (Tonal, Tempo, and the cheaper Rep Fitness/garage-gym category), protein and creatine forward CPG (David Protein, Momentous, Bare Performance Nutrition, Legion), and the recovery stack (Hyperice, Therabody, red light from Joovv and Bon Charge) all benefit.
Alcohol decline. Beer, wine, and spirits volumes have been weak for two years and GLP-1 reduced cravings are a meaningful accelerant. The non-alc category is the obvious beneficiary (Athletic Brewing, Ghia, Seedlip, Free Spirits) and the public-market read on this is already in Constellation, Diageo, and Boston Beer guidance cuts.
Snack and CPG reformulation. Portion sizes are coming down, protein content is going up, and indulgence categories are getting cut. The reformulation winners are anyone protein-forward (Quest, Built Bar, Magic Spoon, David); the losers are the snack majors that move slowly.
Restaurant unit economics. Portion sizes, frequency, and beverage attach are all changing. Casual dining chains with high-volume sugary beverage attach are most exposed.
Third- and fourth-order: where the actual alpha is
The peptide platform layer. Now that 14 peptides are legal again -- and assuming the July PCAC vote does not nuke the compounding pathway -- the opportunity is building the Hims/Ro of peptides. Candidates: My Body Labs (launching July 2026, all 50 states, 503A compounded), RxPepsDirect (503A network, sterility testing published), AXIOM (FDA 510(k) reusable peptide pen -- the technical wedge), T1Rx, PeptideBase on the directory/discovery layer, and Noom's peptide pivot as the public-market read. The category-defining brand here has not been built.
The compliance and enforcement layer. Lilly and Novo are lobbying hard to pull compounded GLP-1s. When that happens -- and it will -- there is a $5 billion-plus orphaned consumer market that needs a compliant alternative. The 503A pharmacy network and the telehealth platforms with clinician relationships are the picks-and-shovels here. The under-built piece is a compliance SaaS layer for the clinic side.
The diagnostic and telehealth router. Hims, Ro, Eden, Mochi, Found, Calibrate, and Sequence/WW are all converging on the same model -- be the router for body composition interventions, not a single-product DTC. The winner is the one that bundles GLP-1, peptides, body-comp diagnostics, derm referral, and behavioral support on one subscription. Function Health and Superpower are pushing at this from the diagnostics side -- see Ringing the Bell's piece on Function for the front-door framing.
The aesthetic identity bundle. The first brand that owns apparel-plus-derm-plus-intimates as a single identity reset wins a much bigger pool than any single category. Skims is the only player approaching this scope right now. The opportunity is a brand-led, bundled, post-GLP-1 wardrobe and aesthetic offering. Nobody has built it yet.
The legacy CPG short. This is the under-discussed trade. Categories that do not adapt -- sugary beverages, chips, ice cream, fast food chains anchored on indulgence -- will lose 5 to 15 percent volume permanently. The right trade is paired: long protein-forward CPG, short the legacy snack majors that move too slowly to reformulate.
Four investable layers -- the takeaway
- Molecule layer. Peptide platforms, novel delivery (AXIOM-style pens), 503A pharmacy networks, the post-July-PCAC supply chain.
- Body composition layer. Strength training, protein, creatine, recovery -- anything that preserves lean mass.
- Aesthetic and identity layer. Apparel, derm, intimates as a bundled refresh; the in-office injectable market.
- Picks-and-shovels routing. Diagnostics (Function, Superpower), telehealth routers (Hims, Ro, Eden), and the compliance SaaS layer underneath all of it.
Connecting back to the midlife thesis
This belongs in the same conversation as the millennial midlife crisis piece. Both topics are about a cohort buying who they want to be next instead of what they're supposed to own. Midlife millennials and GLP-1 adopters are overlapping populations making the same identity-reset purchase decision at scale. Victoria's Secret Q1 is one of the first earnings prints where that decision is showing up cleanly in public-market numbers. It will not be the last.